Jubilant to acquire radiopharmacy business of US-based Triad Isotopes

The acquisition is a strategic fit to Jubilant’s niche nuclear medicine business and will provide Jubilant with direct access to hospital networks with ability to deliver more than 3 million patient doses annually through approximately 1,700 customers. The acquisition will facilitate Jubilant forward integrate in the radiopharmaceutical business, thereby helping it better directly serve healthcare providers and their patients with high quality radiopharmaceutical products.

The US market accounts for approximately 70 percent of the Jubilant Pharma’s radiopharmaceuticals business sales, with Canada accounting for close to 20 percent sales and the rest of the revenues coming from markets in Europe, Latin America and Asia. Jubilant has been further strengthening its radiopharmaceuticals business in the US. 

In January this year, Jubilant DraxImage Inc (JDI), the Montreal (Canada) based wholly-owned subsidiary of Jubilant Pharma, signed long term contracts with distribution networks in the US for supply of products used for diagnostic and therapeutic procedures for thyroid, myocardial perfusion, lung, kidney and bone scans.

Jubilant Pharma’s radiopharmaceuticals business develops, manufactures and markets a portfolio of products that enable nuclear medicine physicians to deliver personalised healthcare to their patients around the globe. Its core products primarily serve patients with cardiac, thyroid and lung disease providing reliable high quality imaging agents and patient specific therapies for nuclear medicine procedures.